August 9, 2020

The Niche

Knoepfler lab stem cell blog

Viacyte

2 min read

A new biotech startup, Semma Therapeutics, announced that it seeks to fight diabetes via translating technology from the lab of Doug Melton at Harvard to the clinic. Update: Note that the firm was recently acquired by Vertex. Another major player in cell therapy-based arena for Diabetes is most likely good news for patients. Quoted in the Boston Globe, there is a good deal of enthusiasm about the potential of this kind of therapeutic approach: “This would be a huge breakthrough,” said Dr. George L. King, a …Read More

7 min read

It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on their clinical trial, the healthy competition with Doug Melton, and future perspectives. Can you give an update on the VC-01 clinical trial? Answer: We’ve enrolled four patients in the …Read More

1 min read

A lot has happened in 2014 in the stem cell and regenerative medicine field and so much of it has been good news. These positive developments are often the result of many years of creative, hard work by amazing teams of researchers. Here is my top 10 list of these exciting advances. 1. First IPSC study in humans by team led by Masayo Takahashi. 2. and 3. Major Diabetes advances: ViaCyte starts stem cell-based clinical trial for Diabetes and multiple teams of researchers make human …Read More

1 min read

Chalk up another exciting development for the stem cell and regenerative medicine field in 2014. It’s been a huge year. For the first time ever, an ES cell-based device has been transplanted into a Diabetic patient. ViaCyte working together with Dr. Robert Henry at UCSD did the pioneering transplant, the first in a series as part of an FDA-approved clinical trial being conducted as UCSD Health System. The trial is a combined Phase I/II testing the safety of ViaCyte’s VC-01 product. The PR says, …Read More